Myomo Inc. MYO shares toppled 42.05% in pre-market trading to $1.02 regardless of reporting second-quarter earnings that went beyond expectations, as financiers concentrated on the medical robotics business’s substantially minimized full-year assistance and widening losses.
Take a look at the existing rate of MYO stock here.
What Took Place: The business published second-quarter earnings of $9.7 million, up 28% year-over-year, beating internal forecasts. Earnings systems increased 13% to 178 MyoPro gadgets, with typical market price increasing 14% to roughly $54,200. Medicare Part B clients represented 56% of quarterly earnings.
Myomo’s money position stays sufficient at $15.5 million since June 30, reinforced by $4.0 million in loanings.
” A number of positive operating metrics were not as strong as we expected due to elements impacting lead quality and pipeline conversion,” stated Paul Gudonis, Myomo’s CEO.
See Likewise: Meta Taps PIMCO, Blue Owl For $29 Billion Louisiana Data Center Buildout As AI Facilities Race Warms Up
The medical robotic assistive gadgets producer trades near the bottom of its annual series of $1.67 to $7.17, with a market capitalization of $63.32 million and a typical volume of 595.1 thousand shares.
Why It Matters: Myomo slashed its 2025 earnings assistance to $40-42 million from the previous series of $50-53 million, mentioning lead quality problems and lower conversion rates. The revised outlook represents simply 23% to 29% development versus 2024, well listed below earlier expectations.
Operating losses expanded considerably to $4.6 million from $1.1 million in the previous year quarter. Bottom line per share increased to $0.11 from $0.03, while changed EBITDA loss broadened to $4.0 million from $1.2 million year-over-year.
Trending Financial Investment Opportunities
The gross margins of Myomo likewise compressed 810 basis indicate 62.7% due to greater product and overhead expenses. Business expenses rose 65% to $10.6 million, driven by increased headcount, research study and advancement costs, and marketing expenses that leapt 162% to $2.2 million.
In spite of producing a record variety of leads, conversion rates dissatisfied. The client pipeline grew 37% to 1,611 prospects, however the stockpile of insurance coverage permissions fell 18% to 230 systems. Management kept in mind that 40-50% of pipeline additions normally originate from leads created a year or more previously.
Rate Action: According to Benzinga Pro information, MYO stock leapt 72.67% throughout routine trading on Monday, closing at $1.76.
Benzinga’s Edge Stock Rankings suggest that Myomo has an unfavorable rate pattern throughout perpetuity frames. Here is how the stock fares on other specifications.
Read Next:
Disclaimer: This material was partly produced with the assistance of AI tools and was examined and released by Benzinga editors.
Image courtesy: Shutterstock